{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:17:54Z","timestamp":1785521874231,"version":"3.56.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s12325-026-03593-5","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T09:27:05Z","timestamp":1779182825000},"page":"3418-3431","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of Documented Infections by Provider Specialty in Patients with Multiple Sclerosis Receiving Disease-Modifying Therapies: A Claims Database Analysis"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4774-7788","authenticated-orcid":false,"given":"Peiqing","family":"Qian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Brunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wennifer","family":"Giglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Holmes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3043-1277","authenticated-orcid":false,"given":"Elijah","family":"Lackey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong-Mi","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2207-3708","authenticated-orcid":false,"given":"Gabriel","family":"Pardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2352-9113","authenticated-orcid":false,"given":"James B.","family":"Lewin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danette","family":"Rutledge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Belviso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5117-9871","authenticated-orcid":false,"given":"Babak","family":"Amerian-Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"issue":"10076","key":"3593_CR1","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1016\/s0140-6736(16)30959-x","volume":"389","author":"WJ Brownlee","year":"2017","unstructured":"Brownlee WJ, Hardy TA, Fazekas F, Miller DH. Diagnosis of multiple sclerosis: progress and challenges. Lancet. 2017;389(10076):1336\u201346. https:\/\/doi.org\/10.1016\/s0140-6736(16)30959-x.","journal-title":"Lancet"},{"issue":"10422","key":"3593_CR2","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/s0140-6736(23)01473-3","volume":"403","author":"D Jakimovski","year":"2024","unstructured":"Jakimovski D, Bittner S, Zivadinov R, et al. Multiple sclerosis. Lancet. 2024;403(10422):183\u2013202. https:\/\/doi.org\/10.1016\/s0140-6736(23)01473-3.","journal-title":"Lancet"},{"issue":"2","key":"3593_CR3","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1056\/NEJMra1401483","volume":"378","author":"DS Reich","year":"2018","unstructured":"Reich DS, Lucchinetti CF, Calabresi PA. Multiple sclerosis. N Engl J Med. 2018;378(2):169\u201380. https:\/\/doi.org\/10.1056\/NEJMra1401483.","journal-title":"N Engl J Med"},{"key":"3593_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00520","volume":"6","author":"AJ Steelman","year":"2015","unstructured":"Steelman AJ. Infection as an environmental trigger of multiple sclerosis disease exacerbation. Front Immunol. 2015;6:520. https:\/\/doi.org\/10.3389\/fimmu.2015.00520.","journal-title":"Front Immunol"},{"issue":"7","key":"3593_CR5","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1177\/1352458518823940","volume":"25","author":"M Marrodan","year":"2019","unstructured":"Marrodan M, Alessandro L, Farez MF, Correale J. The role of infections in multiple sclerosis. Mult Scler. 2019;25(7):891\u2013901. https:\/\/doi.org\/10.1177\/1352458518823940.","journal-title":"Mult Scler"},{"issue":"4","key":"3593_CR6","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1080\/07853890.2018.1461919","volume":"50","author":"AL Pirttisalo","year":"2018","unstructured":"Pirttisalo AL, Sipil\u00e4 JOT, Soilu-H\u00e4nninen M, Rautava P, Kyt\u00f6 V. Adult hospital admissions associated with multiple sclerosis in Finland in 2004-2014. Ann Med. 2018;50(4):354\u201360. https:\/\/doi.org\/10.1080\/07853890.2018.1461919.","journal-title":"Ann Med"},{"issue":"3","key":"3593_CR7","doi-asserted-by":"publisher","first-page":"154","DOI":"10.7224\/1537-2073.2014-109","volume":"18","author":"FR Ernst","year":"2016","unstructured":"Ernst FR, Pocoski J, Cutter G, Kaufman DW, Pleimes D. Analysis of diagnoses associated with multiple sclerosis-related in-hospital mortality using the premier hospital database. Int J MS Care. 2016;18(3):154\u201361. https:\/\/doi.org\/10.7224\/1537-2073.2014-109.","journal-title":"Int J MS Care"},{"issue":"2","key":"3593_CR8","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1159\/000090444","volume":"26","author":"MD Redelings","year":"2006","unstructured":"Redelings MD, McCoy L, Sorvillo F. Multiple sclerosis mortality and patterns of comorbidity in the United States from 1990 to 2001. Neuroepidemiology. 2006;26(2):102\u20137. https:\/\/doi.org\/10.1159\/000090444.","journal-title":"Neuroepidemiology"},{"issue":"5","key":"3593_CR9","doi-asserted-by":"publisher","first-page":"221","DOI":"10.7224\/1537-2073.2014-035","volume":"17","author":"RE Nelson","year":"2015","unstructured":"Nelson RE, Xie Y, DuVall SL, et al. Multiple sclerosis and risk of infection-related hospitalization and death in US veterans. Int J MS Care. 2015;17(5):221\u201330. https:\/\/doi.org\/10.7224\/1537-2073.2014-035.","journal-title":"Int J MS Care"},{"key":"3593_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2022-003370","author":"M Cauchi","year":"2022","unstructured":"Cauchi M, Willis M, Andrews A, et al. Multiple sclerosis and the risk of infection: Association of British Neurologists consensus guideline. Pract Neurol. 2022. https:\/\/doi.org\/10.1136\/practneurol-2022-003370.","journal-title":"Pract Neurol"},{"key":"3593_CR11","doi-asserted-by":"publisher","DOI":"10.1177\/26331055241265668","volume":"19","author":"M Hollist","year":"2024","unstructured":"Hollist M, Hollist A, Au K, et al. Multiple sclerosis and COVID-19: an overview on risk, severity, and association with disease modifying therapies. Neurosci Insights. 2024;19:26331055241265668. https:\/\/doi.org\/10.1177\/26331055241265668.","journal-title":"Neurosci Insights"},{"key":"3593_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.106236","volume":"94","author":"CM Lambert","year":"2025","unstructured":"Lambert CM, Hussain T, Peters J, Longbrake EE. Real-world infection risk in multiple sclerosis patients on long-term immunomodulatory treatments. Mult Scler Relat Disord. 2025;94:106236. https:\/\/doi.org\/10.1016\/j.msard.2024.106236.","journal-title":"Mult Scler Relat Disord"},{"key":"3593_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102462","volume":"46","author":"WLG Medeiros Junior","year":"2020","unstructured":"Medeiros Junior WLG, Demore CC, Mazaro LP, et al. Urinary tract infection in patients with multiple sclerosis: an overview. Mult Scler Relat Disord. 2020;46:102462. https:\/\/doi.org\/10.1016\/j.msard.2020.102462.","journal-title":"Mult Scler Relat Disord"},{"issue":"11","key":"3593_CR14","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s40263-021-00863-4","volume":"35","author":"F Szepanowski","year":"2021","unstructured":"Szepanowski F, Warnke C, Meyer Zu H\u00f6rste G, et al. Secondary immunodeficiency and risk of infection following immune therapies in neurology. CNS Drugs. 2021;35(11):1173\u201388. https:\/\/doi.org\/10.1007\/s40263-021-00863-4.","journal-title":"CNS Drugs"},{"issue":"7","key":"3593_CR15","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1097\/01.Npr.0000000000000202","volume":"49","author":"J Hernandez","year":"2024","unstructured":"Hernandez J. Multiple sclerosis treatment review for primary care providers. Nurse Pract. 2024;49(7):38\u201347. https:\/\/doi.org\/10.1097\/01.Npr.0000000000000202.","journal-title":"Nurse Pract"},{"key":"3593_CR16","doi-asserted-by":"crossref","unstructured":"Aswani VH. Primary care for the multiple sclerosis patient. Med Res Arch. 2020;8(11). https:\/\/esmed.org\/MRA\/mra\/article\/view\/2285\/193545717.","DOI":"10.18103\/mra.v8i11.2285"},{"key":"3593_CR17","unstructured":"Centers for Disease Control, National Center for Health Statistics. Classification of diseases, functioning, and disability: ICD-10-CM 2022. https:\/\/ftp.cdc.gov\/pub\/health_statistics\/nchs\/publications\/ICD10CM\/2022\/icd10cm-tabular-2022-April-1.pdf."},{"key":"3593_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.102741","volume":"49","author":"JC Toliver","year":"2021","unstructured":"Toliver JC, Barner JC, Lawson KA, Rascati KL. Use of a claims-based algorithm to estimate disease severity in the multiple sclerosis Medicare population. Mult Scler Relat Disord. 2021;49:102741. https:\/\/doi.org\/10.1016\/j.msard.2021.102741.","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"3593_CR19","doi-asserted-by":"publisher","first-page":"91","DOI":"10.7224\/1537-2073.2019-030","volume":"22","author":"HB Al Dandan","year":"2020","unstructured":"Al Dandan HB, Coote S, McClurg D. Prevalence of lower urinary tract symptoms in people with multiple sclerosis: a systematic review and meta-analysis. Int J MS Care. 2020;22(2):91\u20139. https:\/\/doi.org\/10.7224\/1537-2073.2019-030.","journal-title":"Int J MS Care"},{"key":"3593_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1380654","volume":"15","author":"A Elgenidy","year":"2024","unstructured":"Elgenidy A, Abdelhalim NN, Al-Kurdi MA, et al. Hypogammaglobulinemia and infections in patients with multiple sclerosis treated with anti-CD20 treatments: a systematic review and meta-analysis of 19,139 multiple sclerosis patients. Front Neurol. 2024;15:1380654. https:\/\/doi.org\/10.3389\/fneur.2024.1380654.","journal-title":"Front Neurol"},{"issue":"8","key":"3593_CR21","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy174","volume":"5","author":"DJ Epstein","year":"2018","unstructured":"Epstein DJ, Dunn J, Deresinski S. Infectious complications of multiple sclerosis therapies: implications for screening, prophylaxis, and management. Open Forum Infect Dis. 2018;5(8):ofy174. https:\/\/doi.org\/10.1093\/ofid\/ofy174.","journal-title":"Open Forum Infect Dis"},{"issue":"4","key":"3593_CR22","doi-asserted-by":"publisher","DOI":"10.1212\/cpj.0000000000200493","volume":"15","author":"A Salter","year":"2025","unstructured":"Salter A, Lancia S, Sharma M, Cutter GR, Fox RJ, Marrie RA. Infection, relapses, and pseudo-relapses in individuals with multiple sclerosis. Neurol Clin Pract. 2025;15(4):e200493. https:\/\/doi.org\/10.1212\/cpj.0000000000200493.","journal-title":"Neurol Clin Pract"},{"key":"3593_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104583","volume":"72","author":"R Knapp","year":"2023","unstructured":"Knapp R, Hardtstock F, Wilke T, et al. Comparing the risk of serious infections in patients with and without MS: a German claims data analysis. Mult Scler Relat Disord. 2023;72:104583. https:\/\/doi.org\/10.1016\/j.msard.2023.104583.","journal-title":"Mult Scler Relat Disord"},{"issue":"9","key":"3593_CR24","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1007\/s00415-015-7796-2","volume":"262","author":"SS Jick","year":"2015","unstructured":"Jick SS, Li L, Falcone GJ, Vassilev ZP, Wallander MA. Epidemiology of multiple sclerosis: results from a large observational study in the UK. J Neurol. 2015;262(9):2033\u201341. https:\/\/doi.org\/10.1007\/s00415-015-7796-2.","journal-title":"J Neurol"},{"key":"3593_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104105","volume":"68","author":"A Khan","year":"2022","unstructured":"Khan A, Lin P, Kamdar N, Peterson M, Mahmoudi E. Potentially preventable hospitalizations and use of preventive services among people with multiple sclerosis: large cohort study, USA. Mult Scler Relat Disord. 2022;68:104105. https:\/\/doi.org\/10.1016\/j.msard.2022.104105.","journal-title":"Mult Scler Relat Disord"},{"key":"3593_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2022.153985","volume":"69","author":"L Oud","year":"2022","unstructured":"Oud L, Garza J. The burden of sepsis in critically ill patients with multiple sclerosis: a population-based cohort study. J Crit Care. 2022;69:153985. https:\/\/doi.org\/10.1016\/j.jcrc.2022.153985.","journal-title":"J Crit Care"},{"issue":"8","key":"3593_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0105207","volume":"9","author":"DS Goodin","year":"2014","unstructured":"Goodin DS, Corwin M, Kaufman D, et al. Causes of death among commercially insured multiple sclerosis patients in the United States. PLoS ONE. 2014;9(8):e105207. https:\/\/doi.org\/10.1371\/journal.pone.0105207.","journal-title":"PLoS ONE"},{"key":"3593_CR28","doi-asserted-by":"publisher","DOI":"10.1177\/17562864241277736","volume":"17","author":"T Derfuss","year":"2024","unstructured":"Derfuss T, Bermel R, Lin CJ, et al. Long-term analysis of infections and associated risk factors in patients with multiple sclerosis treated with ocrelizumab: pooled analysis of 13 interventional clinical trials. Ther Adv Neurol Disord. 2024;17:17562864241277736. https:\/\/doi.org\/10.1177\/17562864241277736.","journal-title":"Ther Adv Neurol Disord"},{"issue":"11","key":"3593_CR29","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1177\/1352458516681198","volume":"23","author":"JM Wijnands","year":"2017","unstructured":"Wijnands JM, Kingwell E, Zhu F, et al. Infection-related health care utilization among people with and without multiple sclerosis. Mult Scler. 2017;23(11):1506\u201316. https:\/\/doi.org\/10.1177\/1352458516681198.","journal-title":"Mult Scler"},{"issue":"Pt 5","key":"3593_CR30","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1093\/brain\/awf098","volume":"125","author":"D Buljevac","year":"2002","unstructured":"Buljevac D, Flach HZ, Hop WC, et al. Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain. 2002;125(Pt 5):952\u201360. https:\/\/doi.org\/10.1093\/brain\/awf098.","journal-title":"Brain"},{"issue":"3","key":"3593_CR31","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1080\/1744666x.2021.1886924","volume":"17","author":"S Otero-Romero","year":"2021","unstructured":"Otero-Romero S, S\u00e1nchez-Montalv\u00e1 A, Vidal-Jordana A. Assessing and mitigating risk of infection in patients with multiple sclerosis on disease modifying treatment. Expert Rev Clin Immunol. 2021;17(3):285\u2013300. https:\/\/doi.org\/10.1080\/1744666x.2021.1886924.","journal-title":"Expert Rev Clin Immunol"},{"issue":"3","key":"3593_CR32","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1177\/1352458520952311","volume":"27","author":"L Moiola","year":"2021","unstructured":"Moiola L, Barcella V, Benatti S, et al. The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: a Delphi consensus statement. Mult Scler. 2021;27(3):331\u201346. https:\/\/doi.org\/10.1177\/1352458520952311.","journal-title":"Mult Scler"},{"issue":"7","key":"3593_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-021-01117-y","volume":"21","author":"TE Smith","year":"2021","unstructured":"Smith TE, Kister I. Infection mitigation strategies for multiple sclerosis patients on oral and monoclonal disease-modifying therapies. Curr Neurol Neurosci Rep. 2021;21(7):36. https:\/\/doi.org\/10.1007\/s11910-021-01117-y.","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"2","key":"3593_CR34","first-page":"173","volume":"106","author":"A Saguil","year":"2022","unstructured":"Saguil A, Farnell Iv EA, Jordan TS. Multiple sclerosis: a primary care perspective. Am Fam Physician. 2022;106(2):173\u201383.","journal-title":"Am Fam Physician"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03593-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03593-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03593-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:08:23Z","timestamp":1785517703000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03593-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["3593"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03593-5","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"assertion":[{"value":"23 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Peiqing Qian has received speaking and consulting honoraria from Biogen, Bristol Myers Squibb, Genentech, Genzyme, TG Therapeutics, and Viela Bio. Jenna Brunn, Wennifer Giglio, and Kelly Holmes have nothing to disclose. Elijah Lackey has received honoraria consulting fees from Amgen, Doximity, EMD Serono, Sanofi, and TG Therapeutics. Jong-Mi Lee has received consulting and speaking advisory board fees from Amgen, Biogen, Novartis, Sanofi, and TG Therapeutics. Gabriel Pardo has received consultation fees from Amgen, Biogen Inc., Bristol Myers Squibb, EMD Serono, Horizon Therapeutics, Novartis, Roche\/Genentech, Sanofi Genzyme, and TG Therapeutics and has received research grant support (to the institution) from Ad Scientiam, Biogen Inc., Bristol Myers Squibb, Contineum Therapeutics, CorEvitas, EMD Serono, Novartis, Roche\/Genentech, Sanofi Genzyme, TG Therapeutics, and ViewMind. James B. Lewin, Danette Rutledge, Nicholas Belviso, and Babak Amerian-Williams are employees of Biogen, Inc. and may hold stock in the company.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective database analysis was based on claims data which precludes the capacity to obtain patients\u2019 consent to participate in the study. This analysis used de-identified claims data from the Komodo Health Claims Database in accordance with the Health Insurance Portability and Accountability Act to protect patient privacy. This analysis did not involve any new studies of humans or animal subjects.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}